Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.

Blood cancer journal·2016

Same author

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

Bone marrow transplantation·2015

Same author

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015

Same author

Classifying ultra-high risk smoldering myeloma.

Leukemia·2014

Search research articles

Related Experiment Video

Updated: May 11, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Cellular immunotherapy for plasma cell myeloma.

A L Garfall¹, D T Vogl, B M Weiss

¹Multiple Myeloma Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Bone Marrow Transplantation

|May 7, 2013

Summary

Cellular immunotherapies offer promising alternatives to allogeneic transplantation for multiple myeloma, aiming for potent antimyeloma immunity with reduced toxicity. Research focuses on engineered T cells and novel immunomodulatory drugs for improved patient outcomes.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Related Experiment Videos

Last Updated: May 11, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

Area of Science:

Immunology
Oncology
Cellular Therapy

Background:

Allogeneic hematopoietic cell transplantation offers graft-vs-myeloma immunity but faces limitations in efficacy and toxicity for plasma cell myeloma.
Current challenges necessitate the development of safer and more effective immunotherapies for multiple myeloma.

Purpose of the Study:

To explore advanced cellular immunotherapy strategies for treating plasma cell myeloma.
To identify approaches that enhance antimyeloma immune responses while minimizing treatment-related risks.

Main Methods:

Investigating the infusion of ex vivo expanded/costimulated autologous T cells post-melphalan.
Developing genetically engineered autologous T cells targeting myeloma-specific epitopes.
Exploring dendritic cell/plasma cell fusions and expanded marrow-infiltrating lymphocytes.
Considering the synergistic potential of immunomodulatory drugs, including PD-1 pathway inhibitors.

Main Results:

Cellular immunotherapies aim to induce specific, reliable, and potent antimyeloma immune responses.
Strategies are designed to reduce the treatment-related risks associated with allogeneic transplantation.
Novel immunomodulatory drugs may enhance the efficacy of cellular immunotherapies.

Conclusions:

Cellular immunotherapies represent a promising avenue for improving outcomes in plasma cell myeloma.
Further research into engineered T cells and immunomodulatory agents is crucial for advancing treatment paradigms.
These innovative approaches hold the potential to overcome the limitations of current transplantation methods.